U.S. markets open in 6 hours 27 minutes

NovoCure Limited (NVCR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
125.65-1.19 (-0.94%)
At close: 4:00PM EST
Sign in to post a message.
  • n
    neoware2021
    see the lead author's publications:Poster Presentations

    (Abstract #: CTIM-17) Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma. J. Kodysh, A. Rubinsteyn, A. Blazquez, J. Mandeli, N. Bhardwaj, A. Hormigo. (Clinical trials: Immunologic)=========
    Search:
    Search PubMed
    Search
    Advanced
    User Guide
    SaveEmailSend to
    Display options
    full text links
    full-text provider logo
    actions
    Cite
    Favorites
    share

    page navigation
    Title & authors
    Abstract
    Similar articles
    Related information
    LinkOut - more resources
    Methods Mol Biol
    . 2020;2120:147-160. doi: 10.1007/978-1-0716-0327-7_10.
    OpenVax: An Open-Source Computational Pipeline for Cancer Neoantigen Prediction
    Julia Kodysh 1, Alex Rubinsteyn 2
    Affiliations expand
    PMID: 32124317 DOI: 10.1007/978-1-0716-0327-7_10
    Abstract
    OpenVax is a computational workflow for identifying somatic variants, predicting neoantigens, and selecting the contents of personalized cancer vaccines. It is a Dockerized end-to-end pipeline that takes as input raw tumor/normal sequencing data. It is currently used in three clinical trials (NCT02721043, NCT03223103, and NCT03359239). In this chapter, we describe how to install and use OpenVax, as well as how to interpret the generated results.

    Keywords: Bioinformatics pipeline; Cancer vaccine; Docker; Immunoinformatics; NGS; Neoantigen.
  • n
    neoware2021
    solid tumor; quorum sensing; intercellular communications; periphery and central tumor areas; p58 affect by hpv and therefore apoptotic influence; novocure affects tubulin which is the basis of microtubules, cell wall/nuclear wall/cellular transportation network.........if using mRNA/DNA, need cell nucleus pore system to open allowing such to get in and out........and to get into cell cytoplasm.....inovio has electroporation for surface but how to expedite and aid the affect on infected or tumor cells?
    famciclovir was supposed to have molecular geometry which facilitated membrane pore entry, but where pcr activity of virus going on change molecular geometry in cytoplasm decreasing the ability of molecule to leave the cell.......hmm......same idea could be applied to prevent entry of virus as some recent phy org articles suggest........geometry is a big deal along with the function of the cell /nuclear barriers......wags.
  • I
    IMO_FWIW
    do not be confused. this science is not changing soon. nvcr had a corner on an entirely alternative treatment. will apply to all solid tumors because they all multiply faster than normal tissue and they all will be susceptible to this treatment. novocure will augment many many solid tumor treatments. the next step after this is crsp cas to stop the mutation allowing the cancer to grow. that's a long ways off.
  • C
    Charles
    Investor's Business Daily posted the following on Friday, 20th Nov.,

    "Novocure, rebounded from its 10-week line this week, broke a down trend line and cleared an early entry – all buying opportunities. Several top stocks are showing similar action."
  • A
    Anonymous
    "Northland Capital slashes price target on NovoCure "
    Who the f is Northland Capital, never heard of them.
    It is a low volume sell off.
    4 days ago IBD said this: "Novocure Flashes Several Buy Signals"
  • J
    James
    The company today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting on November 19 through November 21. The presentations include two oral presentations and cover a broad and growing range of topics, with 36 of the 43 presentations prepared by external authors.
  • G
    Gary01
    looking at the thumbs down, a lot of people don't like me. As if I care! I am not selling anytime soon. This stock is a forever hold for me!
    Bullish
  • M
    Mike
    Here comes the big dash to get back in as people realize they have been played!
    If I only had a dime every time this happens I would be a multi-millionare .....
    See my Post under Annonomus 3th reply.
  • e
    eddypgil
    New high in December
  • J
    Jay
    Seeking Alpha Update:-

    Novocure's non-invasive cancer device Ok'd in Europe for mesothelioma
    Nov. 11, 2020 8:51 AM ETNovoCure Limited (NVCR)By: Vandana Singh, SA News Editor
    • Novocure (NASDAQ:NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma (MPM), in the European Union and Switzerland.
    • The FDA approved the NovoTTF-100L System (known as Optune Lua) for MPM in May 2019 under the Humanitarian Device Exemption pathway.
    • NovoTTF-100L is a noninvasive, antimitotic cancer treatment for MPM, and delivers Tumor Treating Fields using electric fields to disrupt cell division. These Fields does not stimulate or heat tissue and targets dividing cancer cells of a specific size, thus causes minimal damage to healthy cells.
    • Shares are up 4% in premarket.
  • b
    beverlyhistory
    volume remains fairly active. every effort to rally is met with lower bid prices and looks like red is more likely than not....
  • m
    mac
    I call this the big shake out before we hopefully start higher again
    Bullish
  • m
    mac
    122 eod 2nd post
    Bullish
  • W
    William
    Buying opportunity today.
  • K
    Kri
    The same person who insisted I purchase NVCR just told me the Merck venture/testing news will be huge and start the climb to 400. He thought at least an update would be out by the end of year. I know this is not something that can be documented but this person has led me down the right path many times.
  • J
    James
    A virtual research and development day for analysts and investors will take place from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12. The event will review two decades of TTFs research on and introduce exciting new directions of ongoing research and development.

    “With readouts from key clinical trials in multiple indications anticipated over the next few years, we felt it was important to review the extensive body of research conducted over the past two decades that give us confidence and to introduce areas of ongoing research intended to identify optimal use of Tumor Treating Fields and to improve the predictive value of scientific evidence generated,” stated William Doyle, Novocure’s Executive Chairman. “We are also excited to highlight growing interest in Tumor Treating Fields from across the global scientific community as we advance our mission to extend survival in some of the most aggressive forms of cancer.”

    The event will feature six leaders from Novocure’s research and development teams and five external key opinion leaders actively engaged in Tumor Treating Fields research programs. The agenda for Novocure’s virtual research and development day is as follows:

    7:30 a.m. EST
    Welcome and introductory remarks
    Speaker: William Doyle, Novocure’s Executive Chairman

    7:40 a.m. EST
    Tumor Treating Fields’ mechanism of action
    Speaker: Dr. Uri Weinberg, Novocure’s Chief Science Officer

    7:45 a.m. EST
    Applying basic biology to address critical unmet needs
    Speakers: Dr. Moshe Giladi, Novocure’s Director of Preclinical Research and Dr. Carsten Hagemann, University Hospital Würzburg

    8:00 a.m. EST
    Leveraging physics to address critical unmet needs
    Speakers: Dr. Ze’ev Bomzon, Novocure’s Director of Science and Dr. Matthew Ballo, West Cancer Center & Research Institute

    8:10 a.m. EST
    Product innovation to address critical unmet needs
    Speaker: Frank Leonard, Novocure’s Chief Development Officer

    8:20 a.m. EST
    Translational research Q&A
    Facilitator: Dr. Piet Hinoul, Novocure’s Senior Vice President, Global Medical Affairs

    8:40 a.m. EST
    Advancing clinical development
    Speaker: Dr. Ely Benaim, Novocure’s Chief Medical Officer

    8:50 a.m. EST
    Clinical development: combination with chemotherapy
    Speaker: Dr. Hani Babiker, University of Arizona Cancer Center

    8:55 a.m. EST
    Clinical development: combination with immunotherapy
    Speaker: Dr. David Tran, University of Florida College of Medicine

    9:00 a.m. EST
    Clinical development: combination with radiation therapy
    Speaker: Dr. Wenyin Shi, Thomas Jefferson University Hospital

    9:05 a.m. EST
    Clinical development Q&A
    Facilitator: Dr. Piet Hinoul, Novocure’s Senior Vice President, Global Medical Affairs

    9:25 a.m. EST
    Closing remarks
    Speaker: William Doyle

    Access to a virtual exhibition hall, featuring additional resources about Tumor Treating Fields, will be available to registered attendees throughout the event and to explore for the remainder of the day. The event will be webcast live and can be accessed from the Investor Relations page. The webcast will be available for replay for at least 14 days following the event.
  • H
    Howard Kaufman
    Why the 5 point drop in today's up market?
  • J
    JACK
    No news. GH and SWAV also down big time. Chalk it up to profit taking on 2x normal volume. Buy the dip.
  • n
    neoware2021
    ttf as a vibration cancelling field? wags.........would be interesting ....tune to the freq being used by virus and block........if freq changes, tune to next ........including multi freq vibrations? there was a newer antihistamine which was explained as having a long side chain which whipped about increasing it's blockage of histamine receptors, which supposedly made it a more effective histamine blocker...
  • A
    Alana
    Very impressive hiring underway,...that’s just in the US...GoodLuck to All..,

    Key Account ManagerNovocure
    Key Account Manager
    Novocure
    New York, NY
    The Malignant Pleural Mesothelioma (MPM) Key Account Manager is a key position within the US Business Team. The Key Account Manager will be
    1 day ago
    Project Manager, PublicationsNovocure
    Project Manager, Publications
    Novocure
    New York, NY
    Must have excellent written and verbal skills; proficiency in power point, Excel, and Project Management software. 1-2 years of ...
    1 month ago
    Clinical QA AuditorNovocure
    Clinical QA Auditor
    Novocure
    New York, NY
    The role of this position also includes management and conduct of QA audits of clinical trials including but not limited to investigator ...
    1 month ago
    Director, Brand Marketing, GBMNovocure
    Director, Brand Marketing, GBM
    Novocure
    New York, NY
    The Director of Brand Marketing, GBM is responsible for all aspects of marketing that support the use of Novocure’s therapy, Tumor ...
    2 weeks ago
    Director US OperationsNovocure
    Director US Operations
    Novocure
    Portsmouth, NH
    The role is crucial to Novocure’s future success, and involves a broad range of responsibilities. The Director of US Operations is ...
    6 days ago
    Senior Medical Director, Clinical DevelopmentNovocure
    Senior Medical Director, Clinical Development
    Novocure
    New York, NY
    MD or MD/PhD required, with at least 3-5 years clinical experience working as an oncologist or neurologist. Excellent interpersonal ...
    2 weeks ago
    Clinical Research ScientistNovocure
    Clinical Research Scientist
    Novocure
    Chicago, IL
    At least 3 years of experience in clinical research in a similar position. However, PhD or PharmD with extensive experience will be ...
    7 days ago
    Senior Manager, Business Analytics & Data ScienceNovocure
    Senior Manager, Business Analytics & Data Science
    Novocure
    Portsmouth, NH
    This full time, exempt position reports to the Head, Strategic Initiatives and Innovation and is located in a Novocure office in the US (...
    3 weeks ago
    Clinical Research ScientistNovocure
    Clinical Research Scientist
    Novocure
    Lavon, TX
    At least 3 years of experience in clinical research in a similar position. However, PhD or PharmD with extensive experience will be ...
    7 days ago
    IT Project ManagerNovocure
    IT Project Manager
    Novocure
    Malvern, PA
    The individual will also support the evolution and execution of Novocure’s change management process, by supporting the Change Advisory ...
    1 week ago
    Supervisor, Government ReimbursementNovocure
    Supervisor, Government Reimbursement
    Novocure
    Portsmouth, NH
    The Supervisor, Reimbursement is responsible for managing and overseeing core reimbursement processes to establish medical necessity, ...
    3 weeks ago
    Territory ManagerNovocure
    Territory Manager
    Novocure
    Virginia, United States
    Experience and relationships in the neuro-oncology and/or radiation oncology market place would be considered a key asset. Minimum of 5 ...
    4 weeks agoApply Now
    Key Account Manager, MPMNovocure
    Key Account Manager, MPM
    Novocure
    Boston, MA
    Experience and relationships in radiation oncology in academic centers would be considered a key asset as well as thoraric surgery, ...
    1 month ago
    Data Operations ManagerNovocure
    Data Operations Manager
    Novocure
    Portsmouth, NH
    The Data Manager role will handle technical issues that may arise as Novocure deploys software at our first customer sites. Excellent ...
    5 days ago
    Lead Human Factors EngineerNovocure
    Lead Human Factors Engineer
    Novocure
    Portsmouth, NH
    Novocure provides cancer patients with a novel treatment for aggressive cancers using Tumor Treating electric Fields (TTFields). This ...
    2 weeks ago
    Logistics CoordinatorNovocure
    Logistics Coordinator
    Novocure
    Portsmouth, NH
    The Logistics Coordinator is responsible for aiding in the support of Novocure’s Logistics activities at the USOC and USOCII, based in ...
    3 weeks ago
    Single Case Agreement SpecialistNovocure
    Single Case Agreement Specialist
    Novocure
    Portsmouth, NH
    The Single Case Agreement Specialist is responsible for managing core reimbursement processes to negotiate pricing and assist with ...
    2 months ago
    Single Case Agreement SpecialistNovocure
    Single Case Agreement Specialist
    Novocure
    Portsmouth, NH
    The Single Case Agreement Specialist is responsible for managing core reimbursement processes to negotiate pricing and assist with ...
    4 weeks ago
    Senior Nurse Appeals AnalystNovocure
    Senior Nurse Appeals Analyst
    Novocure
    Portsmouth, NH
    The activities also include the preparation and representing Novocure in ALJ hearings. The Senior Nurse Appeals Analyst is responsible ...
    2 weeks ago
    Medical Accounts Receivable Collections SpecialistNovocure
    Medical Accounts Receivable Collections Specialist
    Novocure
    Portsmouth, NH
    The Medical Accounts Receivable Collections Specialist is responsible for managing core re
    Bullish